GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review

November 2021 | 105 pages | ID: G9753EE904AEN
GlobalData

Abstracts

GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GlaxoSmithKline Plc (GSK) is a healthcare company that focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-virals, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc Key Recent Developments

Oct 27,2021: GSK announces Dr Harry (Hal) C. Dietz MD to join the board as non-executive director
Oct 27,2021: GSK delivers strong Q3 sales of ?9.1 billion +5% AER, +10% CER Total EPS 23.3p -7% AER, +3% CER; Adjusted EPS 36.6p +3% AER, +10% CER 2021 full year EPS guidance improved
Oct 26,2021: Berkeley Lights announces GSK acquires third Beacon Optofluidic System to expand antibody therapeutics development
Oct 20,2021: Viome Life Sciences announces expansion of collaboration with GSK into new therapeutic interventions for cancers and autoimmune diseases
Oct 11,2021: Sandoz acquires cephalosporin antibiotics business of GSK

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

GlaxoSmithKline Plc - Key Facts
GlaxoSmithKline Plc - Key Employees
GlaxoSmithKline Plc - Key Employee Biographies
GlaxoSmithKline Plc - Major Products and Services
GlaxoSmithKline Plc - History
GlaxoSmithKline Plc - Company Statement
GlaxoSmithKline Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
GlaxoSmithKline Plc - Business Description
Business Segment: Consumer Healthcare
Overview
Performance
Key Stats
Business Segment: Pharmaceuticals
Overview
Performance
Key Stats
Business Segment: Vaccines
Overview
Performance
Key Stats
Geographical Segment: Rest of World
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US
Performance
R&D Overview
GlaxoSmithKline Plc - Corporate Strategy
GlaxoSmithKline Plc - SWOT Analysis
SWOT Analysis - Overview
GlaxoSmithKline Plc - Strengths
GlaxoSmithKline Plc - Weaknesses
GlaxoSmithKline Plc - Opportunities
GlaxoSmithKline Plc - Threats
GlaxoSmithKline Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
GlaxoSmithKline Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Oct 27, 2021: GSK announces Dr Harry (Hal) C. Dietz MD to join the board as non-executive director
Oct 27, 2021: GSK delivers strong Q3 sales of ?9.1 billion +5% AER, +10% CER Total EPS 23.3p -7% AER, +3% CER; Adjusted EPS 36.6p +3% AER, +10% CER 2021 full year EPS guidance improved
Oct 26, 2021: Berkeley Lights announces GSK acquires third Beacon Optofluidic System to expand antibody therapeutics development
Oct 20, 2021: Viome Life Sciences announces expansion of collaboration with GSK into new therapeutic interventions for cancers and autoimmune diseases
Oct 11, 2021: GSK unveils plan for UK headquarters of new Consumer Healthcare company
Sep 22, 2021: ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021
Sep 20, 2021: GSK announces major renewable energy investment and low carbon inhaler programme alongside Life Sciences sector Race to Zero ‘breakthrough’ at NYC Climate Week
Sep 17, 2021: King's College London and GSK announce new cancer research collaboration
Sep 09, 2021: Bilfinger secures €15m contract from GlaxoSmithKline
Sep 09, 2021: GSK to highlight continued progress in oncology pipeline and portfolio with data presented at ESMO

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

GlaxoSmithKline Plc, Key Facts
GlaxoSmithKline Plc, Key Employees
GlaxoSmithKline Plc, Key Employee Biographies
GlaxoSmithKline Plc, Major Products and Services
GlaxoSmithKline Plc, History
GlaxoSmithKline Plc, Other Locations
GlaxoSmithKline Plc, Subsidiaries
GlaxoSmithKline Plc, Joint Venture
GlaxoSmithKline Plc, Key Competitors
GlaxoSmithKline Plc, Ratios based on current share price
GlaxoSmithKline Plc, Annual Ratios
GlaxoSmithKline Plc, Annual Ratios (Cont...1)
GlaxoSmithKline Plc, Annual Ratios (Cont...2)
GlaxoSmithKline Plc, Interim Ratios
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
GlaxoSmithKline Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

GlaxoSmithKline Plc, Performance Chart (2016 - 2020)
GlaxoSmithKline Plc, Ratio Charts
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021